Drugs.com - New Drug Approvals

Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (diazepam nasal spray) in Ages 2 to 5 Years

San Diego, CA – April, 16, 2025 – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) for short-term treatment of seizure clusters (also known as “acute...

Apr 17, 2025 - 02:57
 0
Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (diazepam nasal spray) in Ages 2 to 5 Years
San Diego, CA – April, 16, 2025 – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) for short-term treatment of seizure clusters (also known as “acute...
Read More

Tags:

Previous Article

Chinese tea chain Chagee aims for $400mn New York IPO despite tariff war

Next Article

STAT+: Trump budget draft proposes NIH consolidation and 40% spending cut

Related Posts

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Sumitomo Pharma America Announces U.S. FDA Approval of ...

Feb 9, 2025  0

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio (nemol...

Feb 9, 2025  0